Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous PolyposisUnderscores unmet need for a ...
Nasdaq4d
Biodexa Pharmaceuticals Receives FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Treatment
Biodexa Pharmaceuticals has announced that the US FDA has granted Fast Track designation for its drug eRapa, an encapsulated form of rapamycin, which is being developed for familial adenomatous ...
Yahoo Finance5d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of ...
Nasdaq4d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...
manilatimes5d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
The designation was requested based on the potential for eRapa to address an unmet medical need for FAP, a condition which left untreated universally leads to colorectal cancer. Today, the only ...
Monthly Prescribing Reference4d
Encapsulated Rapamycin Fast Tracked for Familial Adenomatous Polyposis
Encapsulated rapamycin is expected to prevent disease progression by inhibiting mTOR, a protein kinase that has been shown to be overexpressed in FAP polyps. The Food and Drug Administration (FDA ...
Yahoo Finance5d
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with ...